Kidney International Reports (Nov 2016)
ISN Nexus 2016 Symposia: Translational Immunology in Kidney Disease—The Berlin Roadmap
- Hans-Joachim Anders,
- Brad Rovin,
- David Jayne,
- Paul Brunetta,
- Rosanna Coppo,
- Anne Davidson,
- Satish Kumar Devarapu,
- Dick de Zeeuw,
- Jeremy Duffield,
- Dirk Eulberg,
- Alberto Fierro,
- Jürgen Floege,
- Steffen Frese,
- Loïc Guillevin,
- Stephen Holdsworth,
- Jeremy Hughes,
- Ralph Kettritz,
- Malte Kluger,
- Christian Krebs,
- Larissa Lapteva,
- Adeera Levin,
- Jinhua Li,
- Liz Lightstone,
- Matthias Mack,
- Ladan Mansouri,
- Stephen McAdoo,
- Eoin McKinney,
- Ulf Panzer,
- Samir Parikh,
- Charles Pusey,
- Chaim Putterman,
- Ton Rabelink,
- Andreas Radbruch,
- Andrew Rees,
- Mary Reilly,
- Marlies Reinders,
- Giuseppe Remuzzi,
- Piero Ruggenenti,
- Steven Sacks,
- Thomas J Schall,
- Catherine Meyer-Schwesinger,
- Kumar Sharma,
- Yusuke Suzuki,
- Nicola M. Tomas,
- Ming-Hui Zhao
Affiliations
- Hans-Joachim Anders
- Medizinische Klinik and Poliklinik IV, Klinikum der Ludwig Maximilians Universität München, Munich, Germany
- Brad Rovin
- Ohio State University Wexner Medical Center, Columbus, Ohio, USA
- David Jayne
- Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge, UK
- Paul Brunetta
- Development Team for Rituximab and Obinutuzumab Immunology, Genentech, South San Francisco, California, USA
- Rosanna Coppo
- AOU Città della Salute e della Scienza di Torino, Turin and Fondazione Ricerca Molinette, Regina Margherita Hospital, Turin, Italy
- Anne Davidson
- Center for Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, New York, USA
- Satish Kumar Devarapu
- Medizinische Klinik and Poliklinik IV, Klinikum der Ludwig Maximilians Universität München, Munich, Germany
- Dick de Zeeuw
- Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands
- Jeremy Duffield
- Research & Development, Biogen, Cambridge, Massachusetts, USA
- Dirk Eulberg
- NOXXON Pharma AG, Berlin, Germany
- Alberto Fierro
- Clinica las Condes, Transplantation Unit, Santiago, Chile
- Jürgen Floege
- Department of Nephrology and Clinical Immunology, University Hospital, Rheinisch Westfälische Technische Hochschule Aachen, Aachen, Germany
- Steffen Frese
- Evangelische Lungenklinik Berlin, Klinik für Thoraxchirurgie, Berlin, Germany
- Loïc Guillevin
- Université Paris Descartes and Hôpital Cochin, Paris, France
- Stephen Holdsworth
- Centre for Inflammatory Diseases, Monash University Department of Medicine, Monash Medical Centre, Clayton, Victoria, Australia
- Jeremy Hughes
- Medical Research Council Centre for Inflammation Research, University of Edinburgh, Edinburgh, UK
- Ralph Kettritz
- Department of Nephrology and Critical-Care Medicine, Campus Virchow Klinikum and Experimental and Clinical Research Center, Charité Medical Faculty, Berlin, Germany
- Malte Kluger
- Zentrum für Innere Medizin, III. Medizinische Klinik und Poliklinik, University Medical Center, Hamburg, Germany
- Christian Krebs
- Zentrum für Innere Medizin, III. Medizinische Klinik und Poliklinik, University Medical Center, Hamburg, Germany
- Larissa Lapteva
- Division of Therapeutic Performance, Food and Drug Administration, Silver Spring, Maryland, USA
- Adeera Levin
- Division of Nephrology, University of British Columbia, Vancouver, Canada
- Jinhua Li
- Department of Anatomy and Developmental Biology, Monash University, Clayton, Victoria, Australia
- Liz Lightstone
- Imperial AHSC Lupus Centre, Department of Medicine, Imperial College London, London, UK
- Matthias Mack
- Universität Regensburg, Klinik und Poliklinik für Innere Medizin II, Regensburg, Germany
- Ladan Mansouri
- Unit of Immunology and Allergy, Department of Medicine, Karolinska Institutet, and Karolinska University Hospital Solna, Stockholm, Sweden
- Stephen McAdoo
- Renal and Vascular Inflammation Section, Department of Medicine, Imperial College London, UK
- Eoin McKinney
- Department of Medicine, University of Cambridge School of Clinical Medicine, Addenbrooke's Hospital, Cambridge, UK
- Ulf Panzer
- Zentrum für Innere Medizin, III. Medizinische Klinik und Poliklinik, University Medical Center, Hamburg, Germany
- Samir Parikh
- Ohio State University Wexner Medical Center, Columbus, Ohio, USA
- Charles Pusey
- Renal and Vascular Inflammation Section, Department of Medicine, Imperial College London, UK
- Chaim Putterman
- Division of Rheumatology, Albert Einstein College of Medicine, Bronx, New York, USA
- Ton Rabelink
- Department of Nephrology, Leiden University Medical Center, Leiden, the Netherlands
- Andreas Radbruch
- Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Gemany
- Andrew Rees
- Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria
- Mary Reilly
- Pharmaceutical Development, Opsona Therapeutics Ltd., Dublin 2, Ireland
- Marlies Reinders
- Department of Nephrology, Leiden University Medical Center, Leiden, the Netherlands
- Giuseppe Remuzzi
- IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Clinical Research Center for Rare Diseases Aldo and Cele Daccò, Bergamo, Italy
- Piero Ruggenenti
- IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Clinical Research Center for Rare Diseases Aldo and Cele Daccò, Bergamo, Italy
- Steven Sacks
- MRC Centre for Transplantation Immunology and Mucosal Biology, King’s College London, UK
- Thomas J Schall
- ChemoCentryx, Mountain View, California, USA
- Catherine Meyer-Schwesinger
- Zentrum für Innere Medizin, III. Medizinische Klinik und Poliklinik, University Medical Center, Hamburg, Germany
- Kumar Sharma
- Center for Renal Translational Medicine, Institute of Metabolomic Medicine, University of California, San Diego, San Diego VA Healthcare System, La Jolla, California, USA
- Yusuke Suzuki
- Division of Nephrology, Department of Internal Medicine, Juntendo University Faculty of Medicine, Tokyo, Japan
- Nicola M. Tomas
- Zentrum für Innere Medizin, III. Medizinische Klinik und Poliklinik, University Medical Center, Hamburg, Germany
- Ming-Hui Zhao
- Renal Division, Peking University First Hospital, Beijing, China
- DOI
- https://doi.org/10.1016/j.ekir.2016.06.009
- Journal volume & issue
-
Vol. 1,
no. 4
pp. 327 – 339
Abstract
To date, the treatment of immune-mediated kidney diseases has only marginally benefited from highly specific biological drugs that have demonstrated remarkable effects in many other diseases. What accounts for this disparity? In April 2016, the International Society of Nephrology held a Nexus meeting on Translational Immunology in Nephrology in Berlin, Germany, to identify and discuss hurdles that block the translational flow of target identification, and preclinical and clinical target validation in the domain of immune-mediated kidney disease. A broad panel of experts including basic scientists, translational researchers, clinical trialists, pharmaceutical industry drug developers, and representatives of the American and European regulatory authorities made recommendations on how to overcome such hurdles at all levels of the translational research process. The results of these discussions are presented here, which may serve as a roadmap for how to optimize the process of developing more innovative and effective drugs for patients with immune-mediated kidney diseases.
Keywords
